Skip to main content
. 2022 Oct 10;9:969243. doi: 10.3389/fmed.2022.969243

Figure 1.

Figure 1

FENO cut-off levels in asthma clinical practice. FENO >20 ppb for asthma diagnosis (88% sensitivity and 79% specificity); FENO > 36 and >42 ppb for asthma diagnosis and concomitant rhinitis and CRS, respectively; FENO < 25 ppb less likely for airway eosinophilia; FENO >50 ppb more likely for airway eosinophilia and ICS responsiveness; FENO >28 ppb and >49 ppb predicts exacerbations in steroid-treated and naïve patients, respectively; FENO increase +60% predicts loss of control after steroid withdrawal; FENO increase +30% predicts loss of control in steroid-treated patients; FENO decrease −40% predicts good control in steroid-treated patients; when assessing asthma control/exacerbation smoking habit reduce the quote of FENO of −20%, rhinitis increase of +10%; the FENO values predictors of best response to biologics and the FENO reduction expected (%) are reported (OMA, omalizumab; DUPI, dupilumab; MEPO, mepolizumab; BENRA, benralizumab).